These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 10391533)

  • 1. Influence of chemotherapy on the expression of p53, HER-2/neu and proliferation markers in ovarian cancer.
    Nijman HW; Kenemans P; Poort-Keesom RJ; Verstraeten RA; Mensdorff-Pouilly S; Verheijen RH; Melief CJ; Hilgers J; Meijer CJ
    Eur J Obstet Gynecol Reprod Biol; 1999 Apr; 83(2):201-6. PubMed ID: 10391533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of immunohistochemical expression of topoisomerase alpha II, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu in adrenal and extra-adrenal pheochromocytomas.
    Gupta D; Shidham V; Holden J; Layfield L
    Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):267-74. PubMed ID: 11127918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
    Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
    Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study.
    Riener EK; Arnold N; Kommoss F; Lauinger S; Pfisterer J
    Gynecol Oncol; 2004 Oct; 95(1):89-94. PubMed ID: 15385115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Relationship between expressions of p53, c-erbB2 genes, proliferating cell nuclear antigen and prognosis of patients with ovarian epithelial carcinoma].
    Li JD; Li MD; Li YF; Huang X; Liu JH; Liu FY; Zhang CQ
    Ai Zheng; 2002 Mar; 21(3):292-6. PubMed ID: 12451998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Her-2/neu expression in ovarian cancer: pre- and postexposure to platinum chemotherapy.
    Peethambaram PP; Cliby WA; Lubiniecki G; Clayton AC; Roche PC; Iturria SJ; Hartmann LC; Hellström I; Strome SE
    Gynecol Oncol; 2003 Apr; 89(1):99-104. PubMed ID: 12694661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic values of p53 and HER-2/neu coexpression in invasive bladder cancer in Taiwan.
    Tsai YS; Tzai TS; Chow NH; Yang WH; Tong YC; Lin JS; Chang CC; Cheng HL; Lin YM
    Urol Int; 2003; 71(3):262-70. PubMed ID: 14512646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer.
    Han H; Landreneau RJ; Santucci TS; Tung MY; Macherey RS; Shackney SE; Sturgis CD; Raab SS; Silverman JF
    Hum Pathol; 2002 Jan; 33(1):105-10. PubMed ID: 11823980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany.
    Pfisterer J; Du Bois A; Bentz EK; Kommoss F; Harter P; Huober J; Schmalfeldt B; Burchardi N; Arnold N; Hilpert F
    Int J Gynecol Cancer; 2009 Jan; 19(1):109-15. PubMed ID: 19258951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondrial DNA alterations correlate with the pathological status and the immunological ER, PR, HER-2/neu, p53 and Ki-67 expression in breast invasive ductal carcinoma.
    Lin CS; Chang SC; Ou LH; Chen CM; Hsieh SS; Chung YP; King KL; Lin SL; Wei YH
    Oncol Rep; 2015 Jun; 33(6):2924-34. PubMed ID: 25845386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer.
    Cloven NG; Kyshtoobayeva A; Burger RA; Yu IR; Fruehauf JP
    Gynecol Oncol; 2004 Jan; 92(1):160-6. PubMed ID: 14751152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer.
    Ferrandina G; Ranelletti FO; Gallotta V; Martinelli E; Zannoni GF; Gessi M; Scambia G
    Gynecol Oncol; 2005 Sep; 98(3):383-9. PubMed ID: 15979129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis.
    de Graeff P; Crijns AP; de Jong S; Boezen M; Post WJ; de Vries EG; van der Zee AG; de Bock GH
    Br J Cancer; 2009 Jul; 101(1):149-59. PubMed ID: 19513073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma.
    García-Velasco A; Mendiola C; Sánchez-Muñoz A; Ballestín C; Colomer R; Cortés-Funes H
    Clin Transl Oncol; 2008 Jun; 10(6):367-71. PubMed ID: 18558584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression and relationships of HER-2/neu, epidermal growth factor receptor, p53, Ki-67, and tumor necrosis factor alpha in epithelial ovarian cancer.
    Goff BA; Shy K; Greer BE; Muntz HG; Skelly M; Gown AM
    Eur J Gynaecol Oncol; 1996; 17(6):487-92. PubMed ID: 8971524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of p53 and selected proliferative markers (Ki-67, MCM3, PCNA, and topoisomerase IIα) in borderline ovarian tumors: Correlation with clinicopathological features.
    Ciepliński K; Jóźwik M; Semczuk-Sikora A; Gogacz M; Lewkowicz D; Ignatov A; Semczuk A
    Histol Histopathol; 2018 Feb; 33(2):171-179. PubMed ID: 28493257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of HER-2, p53 and Bcl-2 in patients with epithelial ovarian cancer.
    Malamou-Mitsi V; Crikoni O; Timotheadou E; Aravantinos G; Vrettou E; Agnantis N; Fountzilas G
    Anticancer Res; 2007; 27(2):1157-65. PubMed ID: 17465257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.
    Khalifa MA; Mannel RS; Haraway SD; Walker J; Min KW
    Gynecol Oncol; 1994 Apr; 53(1):84-92. PubMed ID: 7909788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer.
    Fijołek J; Wiatr E; Rowińska-Zakrzewska E; Giedronowicz D; Langfort R; Chabowski M; Orłowski T; Roszkowski K
    Int J Biol Markers; 2006; 21(2):81-7. PubMed ID: 16847810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA hypermethylation, Her-2/neu overexpression and p53 mutations in ovarian carcinoma.
    Feng Q; Deftereos G; Hawes SE; Stern JE; Willner JB; Swisher EM; Xi L; Drescher C; Urban N; Kiviat N
    Gynecol Oncol; 2008 Nov; 111(2):320-9. PubMed ID: 18757082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.